Abstract
Background: RET fusions are a known tumor driver in 1–2% of patients with advanced non-small cell lung cancer (aNSCLC). The advent of selective RET inhibitors (RETi) significantly improved prognosis, but around 20% of patients show primary resistance. Moreover, secondary resistance inevitably occurs and molecular mechanisms are still incompletely characterized.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
